MilliporeSigma awarded U.S. patent for new CRISPR technology

By The Science Advisory Board staff writers

April 8, 2020 -- MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second CRISPR patent granted to the company in the U.S. and its 23rd CRISPR-related patent worldwide.

This places MilliporeSigma as the only provider with a patent for the fusion of chromatin-modulating peptides to CRISPR proteins. The ability to fuse chromatin, which often blocks DNA, with CRISPR-chrom technology improves efficiency of the gene-editing process, according to the company. The initial work on the technology was published in the CRISPR Journal in late February.

MilliporeSigma's full CRISPR patent portfolio includes CRISPR-related technologies covering foundational intellectual property and alternative genome-editing methods.

MilliporeSigma launches Lanexo software at Pittcon 2020
MilliporeSigma launched its Lanexo software for lab inventory, safety, and compliance management at the Pittcon meeting in Chicago on March 3. The new...
MilliporeSigma to make Elypta liquid biopsy kits
MilliporeSigma has signed an agreement with Swedish molecular diagnostics company Elypta to be the contract manufacturer for Elypta's clinical diagnostic...
MilliporeSigma unveils BrightLab for research scientists
MilliporeSigma has introduced BrightLab, a cloud-based inventory management and instrument connectivity platform for research scientists.
ReForm Biologics, MilliporeSigma ink license agreement
ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications. The agreement...
MilliporeSigma licenses CRISPR tech to Promega
MilliporeSigma announced on December 19 that it has signed a license agreement providing Promega Corp., access to MilliporeSigma's foundational CRISPR...
MilliporeSigma licenses CRISPR IP to Evotec
MilliporeSigma announced today that it signed a license agreement providing Evotec SE access to MilliporeSignma's foundational CRISPR intellectual protect....

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter